Sanjay Patel MD

Sanjay Patel MD has extensive experience in the field of clinical development and medical affairs. Sanjay is currently serving as the Medical Director at Inventiva Pharma, where they are leading the early phase studies and supporting the pivotal phase 3 program for the development of a new oral small molecule therapy for NASH.

Prior to their current role, Sanjay held positions at Biocon Biologics, Freeline, Shionogi Inc., ProMetic, Daiichi Sankyo Development Ltd, Boehringer Ingelheim, GSK, Eli Lilly and Company, and Roche Pharmaceuticals.

During their career, Sanjay has worked on a variety of therapeutic areas, including orphan diseases, metabolism, chronic fibrosis conditions, diabetic complications, neuropathy, neuropathic and post-surgical pain conditions, nephrology, infectious diseases, and respiratory disease. Sanjay has led global clinical/medical development teams and has been responsible for clinical strategic planning and development of compounds. Sanjay has also served in medical affairs roles in areas such as diabetes, obesity, neurology, and rheumatology.

Overall, Sanjay Patel MD has demonstrated a strong track record in clinical development and medical affairs, with expertise in various therapeutic areas and a focus on innovative treatments for challenging medical conditions.

Sanjay Patel MD completed their education in medicine from the University of Leeds, earning an MB ChB degree. Sanjay attended the university from 1988 to 1993, focusing on the field of study in medicine.